{"url_path":"/sec/lgnd/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-302660-index.html","accession_number":"0001193125-26-302660","cik":"0000886163","ticker":"LGND","issuer_name":"LIGAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-302660-index.html","primary_entity_key":"0000886163","primary_entity_name":"LIGAND PHARMACEUTICALS INC"},"word_count":394,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(a) Financial statements of business acquired.\n\nThe Company will provide the financial statements required to be filed by Item 9.01(a) of Form 8-K by amendment to this Current Report on Form 8-K no later than the 71st day after the required filing date for this Current Report on Form 8-K.\n\n(b) Pro forma financial information\n\nThe Company will provide the pro forma financial statements required to be filed by Item 9.01(b) of Form 8-K by amendment to this Current Report on Form 8-K no later than the 71st day after the required filing date for this Current Report on Form 8-K.\n\n(d) Exhibits.\n\n \n\nExhibit\n  \nDescription\n\n2.1*\n  \n[Agreement and Plan of Merger, dated as of April 27, 2026, by and among XOMA Royalty Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2026).](http://www.sec.gov/Archives/edgar/data/886163/000119312526179529/d143046dex21.htm)\n\n2.2\n  \n[Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2026).](http://www.sec.gov/Archives/edgar/data/886163/000119312526228003/d86489dex21.htm)\n\n10.1*\n  \n[Form of Support Agreement, dated as of April 27, 2026, entered into by Ligand Pharmaceuticals Incorporated, Flex Merger Sub, Inc. and the Supporting Stockholders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2026).](http://www.sec.gov/Archives/edgar/data/886163/000119312526179529/d143046dex101.htm)\n\n99.1\n  \n[Press Release of Ligand Pharmaceuticals Incorporated, dated July 14, 2026.](d108457dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nCertain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nLIGAND PHARMACEUTICALS INCORPORATED\n\nDate: July 14, 2026\n \n\n \nBy:\n \n/s/ Andrew Reardon\n\n \n\n \n\n \nName:\n \nAndrew Reardon\n\n \n\n \n\n \nTitle:\n \nChief Legal Officer and Secretary"}